GSK drops camlipixant RCC development after mixed Phase III results
GSK•Next steps and ongoing trial
Results will be submitted for future presentation or publication to inform ongoing research into refractory chronic cough.
The phase IIb BALANCE trial will continue to test camlipixant in IBS-D and IBS-M.
Camlipixant refractory chronic cough program to stop
GSK will stop development of camlipixant for refractory chronic cough following limited efficacy across the CALM phase III program.
- CALM-1 supported 50 mg twice daily at week 12.
- CALM-2 failed to reach significance at week 24.
- 25 mg twice daily missed in both studies.
